Litiam ER400 mg

Litiam ER is a mood-stabilizing agent used in the treatment of bipolar disorder. Its evidence-based uses include:

• Established/FDA-approved use: Treatment of acute manic and mixed episodes of bipolar I disorder, as monotherapy, in patients 7 years of age and older.
• Established/FDA-approved use: Maintenance (prophylactic) treatment of bipolar I disorder to reduce the frequency and severity of future manic episodes.
• Guideline-supported adjunct use: Augmentation therapy added to an antidepressant in treatment-resistant major depressive disorder, when depression has not adequately responded to antidepressant therapy alone; this requires combination with an antidepressant and is not used as monotherapy for depression.
• Historic/off-label use: Prophylaxis of recurrent unipolar depressive episodes in some patients, based on long clinical experience, though this is less strongly evidence-supported than its bipolar indications.

Litiam ER is not indicated for rapid control of acute agitation on its own, as its onset of clinical effect is delayed (days to weeks); antipsychotics or benzodiazepines are typically used for immediate control while Litiam ER levels are established.

Each capsule/tablet of Lithium Carbonate contains Lithium Carbonate as the active ingredient. In Bangladesh, Lithium Carbonate is commonly available as sustained-release (SR/ER) tablets of 400 mg strength; immediate-release capsules and tablets (e.g., 300 mg) and oral liquid preparations are also available in some markets. Formulations contain standard inactive excipients that may vary by manufacturer.

Litiam ER is a monovalent cation salt that has been used as a mood stabilizer for more than 50 years in the treatment of bipolar disorder. It has a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small, so treatment requires regular monitoring of serum lithium concentration alongside renal and thyroid function. Litiam ER is administered orally as immediate-release or sustained-release tablets/capsules.

Litiam ER belongs to the therapeutic class of mood stabilizers / antimanic agents.

Mechanism of Action

The precise mechanism of action of Lithium Carbonate is not fully established. Proposed mechanisms include inhibition of glycogen synthase kinase-3 (GSK-3) and inositol monophosphatase, alteration of second-messenger signaling (the phosphoinositide cycle), modulation of neurotransmitter release (including serotonin, dopamine, and glutamate), and effects on sodium transport across neuronal and muscle cell membranes. These actions are believed to contribute to its mood-stabilizing and neuroprotective effects.

Pharmacokinetics

Lithium Carbonate is well absorbed after oral administration (essentially complete for immediate-release forms; sustained-release forms are absorbed more slowly and completely over several hours). It is not protein-bound and is not metabolized; it is excreted almost entirely unchanged by the kidneys, competing with sodium for renal reabsorption. The elimination half-life is approximately 18-24 hours in healthy adults (longer in elderly patients and those with reduced renal function), and steady-state serum levels are generally reached after about 5 days of consistent dosing.

Litiam ER is given orally, ideally with or right after food to minimize nausea and stomach upset. Sustained-release tablets must be swallowed whole with a full glass of water, not crushed, split, or chewed. Take Litiam ER at the same times every day, maintain normal, consistent fluid and dietary salt intake, and do not stop or change the dose without consulting a physician, as abrupt discontinuation can increase the risk of relapse of mood symptoms.

• NSAIDs (e.g., ibuprofen, diclofenac, naproxen): Reduce renal clearance of lithium and can significantly raise serum lithium levels, increasing toxicity risk; concurrent use requires close monitoring or should be avoided where possible.
• ACE inhibitors and Angiotensin Receptor Blockers (ARBs): Can reduce renal lithium excretion, leading to elevated lithium levels and toxicity; monitor serum lithium closely if combined.
• Thiazide diuretics: Reduce sodium and lithium excretion, substantially increasing serum lithium concentration; combination requires dose reduction of Litiam ER and careful monitoring.
• Metronidazole: May reduce renal clearance of lithium, raising serum levels; monitor closely if co-administered.
• Serotonergic drugs (e.g., SSRIs, SNRIs, triptans): Combination with Litiam ER carries a risk of serotonin syndrome; monitor for symptoms such as agitation, tremor, hyperthermia, and autonomic instability.
• Antipsychotics (e.g., haloperidol): Rare reports of severe neurotoxicity (encephalopathic syndrome) with combined use; monitor closely for confusion, rigidity, and abnormal movements.
• Sodium bicarbonate / high-sodium intake: Increases renal lithium excretion and can lower lithium levels below the effective range; sudden changes in sodium intake should be avoided.

Adverse effects of Litiam ER are closely related to serum concentration. Common and important effects include:

• Common (often dose-related): Fine hand tremor, increased thirst (polydipsia) and increased urination (polyuria), nausea, mild diarrhea or loose stools, general tiredness/weakness, metallic taste, mild cognitive dulling or memory complaints, and modest weight gain.
• Endocrine effects (with longer-term use): Hypothyroidism or goiter (periodic thyroid monitoring required — see Precautions), and, less commonly, hyperparathyroidism with elevated calcium.
• Renal effects (with longer-term use): Nephrogenic diabetes insipidus (excessive dilute urination) and, rarely, chronic kidney changes with prolonged therapy.
• Other reported effects: Fine skin rash or acne, hair thinning, benign leukocytosis, and reversible ECG changes (e.g., T-wave flattening).

Signs of developing toxicity (e.g., coarse tremor, ataxia, confusion, persistent vomiting) are distinct from these common effects and require prompt medical evaluation; see Overdose/Toxicity.

Pregnancy: Litiam ER has been associated with an increased risk of fetal cardiac malformations, particularly Ebstein's anomaly, with exposure during the first trimester. Litiam ER should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; this decision should always be made together with a physician, with careful risk-benefit discussion, fetal cardiac screening if used in the first trimester, and closer serum lithium monitoring throughout pregnancy and around delivery, since fluid shifts can significantly change lithium levels.

Lactation: Litiam ER passes into breast milk in significant amounts and infant serum lithium levels can approach maternal levels, with a risk of toxicity in the nursing infant. Breastfeeding during Litiam ER therapy is generally not recommended; if a mother chooses to breastfeed, this should only be done under close physician supervision with monitoring of the infant.

Narrow Therapeutic Index and Toxicity Risk

Litiam ER has a narrow margin between therapeutic and toxic serum concentrations. Regular monitoring of serum lithium levels is essential, and patients/caregivers should be counseled on early signs of toxicity (see Overdose/Toxicity) and instructed to seek prompt medical attention if these occur.

Renal Function

Since Litiam ER is renally cleared, any condition that reduces renal function (including age-related decline, dehydration, or intercurrent illness) can raise lithium levels and toxicity risk. Renal function should be assessed before starting treatment and monitored periodically thereafter; dose reduction may be needed with declining renal function.

Cardiovascular Disease

Litiam ER can cause reversible ECG changes and, rarely, sinus node dysfunction. Patients with significant pre-existing cardiovascular disease should be evaluated carefully before starting therapy and monitored closely, weighing potential benefits against cardiac risk on an individual basis.

Thyroid Function

Litiam ER can cause hypothyroidism or goiter with long-term use. Thyroid function tests should be obtained at baseline and monitored periodically (e.g., every 6-12 months) during treatment; thyroid hormone replacement can usually be co-administered if hypothyroidism develops without needing to stop Litiam ER.

Fluid and Sodium Balance

Conditions causing significant fluid or sodium loss — such as prolonged sweating, fever, vomiting, diarrhea, reduced fluid intake, or use of diuretics/low-salt diets — can substantially raise serum lithium levels and precipitate toxicity. Patients should maintain consistent daily fluid and salt intake and seek medical advice promptly if significant fluid losses occur, as temporary dose reduction or suspension may be required.

Serotonin Syndrome and Neurotoxicity

Combining Litiam ER with serotonergic drugs or certain antipsychotics carries risk of serotonin syndrome or a severe neurotoxic (encephalopathic) reaction; see Interactions. Monitor for confusion, agitation, tremor, rigidity, fever, and autonomic instability.

Central Nervous System Effects

Litiam ER can cause drowsiness, tremor, or impaired coordination, particularly at higher levels. Patients should use caution when driving or operating machinery until they know how Litiam ER affects them.

Overdose or accumulation of Litiam ER to toxic serum concentrations (generally at or above 1.5 mEq/L) is a medical emergency. Early signs include coarse hand tremor, muscle weakness, lack of coordination (ataxia), diarrhea, vomiting, drowsiness, and slurred speech. More severe toxicity can progress to confusion, muscle twitching, seizures, cardiac rhythm disturbances, significantly reduced consciousness, and coma, and can be fatal.

If overdose or toxicity is suspected, seek immediate medical attention or contact emergency services / a poison control center right away — do not wait for symptoms to worsen. There is no specific antidote for lithium toxicity. Management is supportive and is provided in a hospital setting, with close monitoring of serum lithium levels, electrolytes, and renal function; hemodialysis may be required to rapidly lower lithium levels in severe cases. Do not attempt to manage suspected Litiam ER toxicity at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pregnancy

Litiam ER should be used in pregnancy only if clearly needed, given the risk of fetal cardiac malformations. See Pregnancy and Lactation.

Lactation

Breastfeeding is generally not recommended during Litiam ER therapy. See Pregnancy and Lactation.

Renal Impairment

Dose reduction and more frequent monitoring are required in renal impairment; Litiam ER is contraindicated in severe renal impairment or renal failure (see Contraindications).

Hepatic Impairment

Litiam ER is not hepatically metabolized, so dedicated hepatic dose adjustment is not established; use with general caution and clinical monitoring in significant liver disease.

Elderly

Elderly patients often have reduced renal clearance and increased sensitivity to Litiam ER. A lower starting dose, a lower target serum level, and closer monitoring are generally recommended.

Pediatric

See Pediatric Uses.

For acute mania, Litiam ER is typically continued until manic symptoms are controlled, then transitioned to a maintenance regimen. Maintenance/prophylactic treatment of bipolar I disorder with Litiam ER is often long-term, sometimes indefinite, given the recurrent nature of bipolar disorder, and requires ongoing physician follow-up with periodic reassessment of continued need, serum lithium levels, and renal/thyroid function throughout treatment. When used as an adjunct for treatment-resistant depression, duration is guided by response and is determined together with the treating physician.

Lithium Carbonate is classified as a mood stabilizer / antimanic agent (a monovalent cation salt).

The exact mode of action of Lithium Carbonate is not completely understood. It is thought to stabilize mood through inhibition of glycogen synthase kinase-3 (GSK-3) and inositol monophosphatase, modulation of intracellular second-messenger (phosphoinositide) signaling, effects on neurotransmitter systems (including serotonin, dopamine, and glutamate), and alteration of sodium ion transport across excitable cell membranes, collectively contributing to its antimanic and mood-stabilizing effects.

Category D (per FDA legacy pregnancy categorization system) — positive evidence of human fetal risk, but potential benefits may warrant use in select patients despite the risk.

Litiam ER is approved for the treatment of acute manic and mixed episodes of bipolar I disorder, as monotherapy, in patients 7 years of age and older; safety and efficacy have not been established in children younger than 7 years. Patients weighing more than 30 kg may generally be dosed similarly to adults, while those weighing 20-30 kg typically require a lower starting dose with careful upward titration. Children and adolescents on Litiam ER require close monitoring of serum lithium levels, renal function, thyroid function, growth, and weight, given their potentially greater sensitivity to adverse effects. Use should be supervised by a physician experienced in pediatric psychiatric care.